U3A Cell line human

12021503, human fibrosarcoma, Epithelial

• Synonym(s): 2fTGH, 2fTGH-U3A
• UNSPSC Code: 41106514

Properties

• Product Name: U3A Cell line human, 12021503
• biological source: human fibrosarcoma
• morphology: Epithelial
• shipped in: dry ice
• storage temp.: −196°C

Description

Cell Line Description

The human sarcoma cell line HT 1080 (ECACC Catalogue number 85111505) was transfected with a vector encoding a selectable marker (guanine phosphoribosyltransferase) regulated by alpha interferon to create the 2fTGH cell line, enabling the selection of mutations in genes encoding components of the interferon signalling pathway. Chemical mutagenesis of the parent 2fTGH cell line enabled the isolation of a number of IFNg signalling mutants available from ECACC: U2A (12021502), U3A (12021503), U4A (12021504), U4C (12021505), U5A (12021506), U6A (12021507). Each contains a different mutation in the IFN signalling pathway. The 2fTGH panel provides a tool for the in vitro study and comparison of disrupted interferon signalling at multiple points across the IFN pathway. The U3A mutant cell line lacks expression of STAT1 gene product. U3A is unresponsive to interferon-alpha and interferon-gamma. U3A is partially defective in its response to double stranded RNA.

DNA Profile

STR-PCR Data:
Amelogenin: X,Y
CSF1PO: 12
D13S317: 12,14
D16S539: 9,12
D5S818: 11,13
D7S820: 9,10
THO1: 6
TPOX: 8
vWA: 14,19

Culture Medium

DMEM (D6546) + 2mM L-Glutamine (G7513) + 10% FBS (F2442).

Subculture Routine

Split sub-confluent cultures (70-80%) 1:4 to 1:8 i.e. seeding at 1-4x10,000 cells/cm² using 0.05% trypsin/EDTA; 5% CO₂; 37°C.

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Citation

If use of this culture results in a scientific publication, it should be cited in the publication as: U3A (ECACC 12021503)

Disclaimer

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.